A new trend in weight loss, known as microdosing, is spreading from the US to the UK, raising safety concerns. The practice involves taking less than the recommended dose of GLP-1 medications such as Ozempic, Mounjaro, or Wegovy, in an off-label manner. There is little scientific evidence to support its efficacy or safety.
Private clinics in the UK are now offering microdosing treatments. The Healand clinic in Leicester, for example, charges from £175 a month and has 750 patients on the regimen, starting at a fifth of the normal dose. The Aestha clinic in London and pharmacies in Hertfordshire and Kent also provide similar services.
Proponents claim microdosing helps with gradual weight loss, reduces side effects like vomiting, and curbs alcohol consumption. Dr Omar Babar of Healand says it benefits perimenopausal women and high-functioning professionals. However, critics warn that off-label use lacks robust research and may be risky.
The trend gained traction after a podcast by Dr Andrew Huberman featured Dr Craig Koniver, who called it a 'gamechanger'. Users like Jade, a 32-year-old from London, report positive results, including reduced inflammation from endometriosis and weight loss, but experts urge caution due to the lack of clinical trials.
